Cancer care is pricing in management. These trials ask what happens if it gets cures.
Cancer care has spent decades getting better at holding the line: shrink the tumor, delay the relapse, keep the next treatment ready. Two small immunotherapy trials are asking a sharper question. What if, for some cancers, the business of managing cancer starts to give way to the much stranger business of making it disappear?
That is not where the evidence fully is yet. The trials are tiny. One is in pancreatic cancer patients healthy enough for surgery. The other is in high-risk smoldering multiple myeloma, a blood-plasma-cell disorder that can turn into active multiple myeloma. The podcast version of this story managed to misplace the second result onto melanoma. Biology is rude about that kind of thing. The source paper and Dana-Farber materials are clear: it was myeloma, not melanoma.
The first dataset comes from Memorial Sloan Kettering Cancer Center, where researchers followed patients who received a personalized messenger RNA cancer vaccine after pancreatic cancer surgery. Messenger RNA, or mRNA, is the molecule that tells cells which protein to make. In a cancer vaccine, the point is not to prevent infection, as with the COVID shots, but to train the immune system to recognize mutations unique to a patient's tumor. Of the 8 out of 16 patients whose immune systems mounted a strong response to the vaccine, 7 were still alive four to six years after surgery, MSK Cancer Center News reported. NBC News put one human face on that number: Donna Gustafson, one of the trial participants, marked her 50th wedding anniversary by hiking Mount Etna.
The second dataset comes from Dana-Farber Cancer Institute, where a phase 2 trial tested ciltacabtagene autoleucel, a CAR-T cell therapy, in 20 people with high-risk smoldering multiple myeloma. CAR-T means doctors remove a patient's T cells, engineer them to recognize a cancer-linked target, and infuse them back into the body. Minimal residual disease, or MRD, is the small amount of cancer that can remain after treatment and later drive relapse. In this trial, all 20 patients became MRD-negative within two months and remained MRD-negative after a median follow-up of 15.3 months, with no progressions or deaths, Dana-Farber said. The results were published in Nature Medicine and presented at the American Association for Cancer Research annual meeting.
Neither trial proves a cure. The pancreatic vaccine worked immunologically in half the patients enrolled. The myeloma study followed 20 people, and 15.3 months is encouraging, not final. Phase 1 and phase 2 oncology trials are where beautiful ideas often learn manners. The point is narrower and more interesting: both results are durability signals, and durability is the thing cancer medicine usually struggles to buy.
Cancer drugs often win approvals by delaying progression, because waiting for overall survival can take years and because many patients move through several lines of therapy. These two studies are different in kind. The pancreatic vaccine responders are not merely showing a scan response a few months later. Most were alive years after a diagnosis that usually carries a brutal prognosis. The CAR-T trial is not just shrinking tumor burden in active disease. It is trying to intercept a high-risk precursor state before it becomes active cancer.
That interception frame matters. Dana-Farber said about 50 percent of patients with high-risk smoldering multiple myeloma progress to active multiple myeloma within two years without treatment, according to its trial announcement. If a one-time cell therapy can keep that group MRD-negative long enough, the commercial question becomes awkward. Oncology has been built around repeated treatment: infusions, maintenance drugs, monitoring, relapse management, and the next regimen after that.
The market is large enough that even a partial shift matters. IQVIA's 2024 global oncology trends report estimated global spending on cancer medicines at $223 billion in 2023 and projected it would reach $409 billion by 2028. That does not mean today's small trials will vaporize hundreds of billions of dollars. It does mean the incentives around oncology were built for chronic management, and durable immune therapies put pressure on that model.
There is a reason to be careful. CAR-T has been strongest in blood cancers, where the target cells are easier for engineered immune cells to reach. Solid tumors such as pancreatic, lung, and breast cancers remain harder because their surrounding tissue can block or suppress immune attack. The pancreatic vaccine also applies first to patients who can have surgery, which is only a subset of pancreatic cancer patients. The clinical door is open, not wide.
Still, the pipeline is no longer hypothetical. A 2025 review indexed in PMC said more than 120 mRNA cancer vaccine clinical trials have been conducted or launched across cancers including lung, breast, prostate, melanoma, pancreatic, and brain tumors. The old cancer-vaccine field was littered with elegant immune theories and disappointing human data. The new version has better sequencing, faster vaccine manufacturing, and a pandemic-tested delivery platform. That does not guarantee success. It gives the field a better machine for finding out.
The cleanest read is not that cancer is suddenly solved. It is that oncology's default assumption, manage the disease for as long as possible, is starting to meet therapies designed around eradication or interception. If those therapies scale, the winners will not just be the companies with the best response rates. They will be the ones that can make one-time or short-course treatments manufacturable, reimbursable, and available before cancer has settled in for a long stay.